<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Neurology</journal-id><journal-id journal-id-type="iso-abbrev">Neurology</journal-id><journal-id journal-id-type="hwp">neurology</journal-id><journal-id journal-id-type="publisher-id">neur</journal-id><journal-id journal-id-type="pmc">neurology</journal-id><journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id><journal-title-group><journal-title>Neurology</journal-title></journal-title-group><issn pub-type="ppub">0028-3878</issn><issn pub-type="epub">1526-632X</issn><publisher><publisher-name>Lippincott Williams &amp; Wilkins</publisher-name><publisher-loc>Hagerstown, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6453770</article-id><article-id pub-id-type="pmid">30796143</article-id><article-id pub-id-type="publisher-id">NEUROLOGY2018928317</article-id><article-id pub-id-type="doi">10.1212/WNL.0000000000007186</article-id><article-categories><subj-group subj-group-type="hwp-journal-coll"><subject>20</subject><subject>139</subject><subject>322</subject><subject>205</subject></subj-group><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Effect of prolonged antibiotic treatment on cognition in patients with Lyme borreliosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Berende</surname><given-names>Anneleen</given-names></name><degrees>MD, MSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) the Netherlands National Organization for Scientific Research, grantnumber: ZonMw 171002304, Investigator, 2010- 2015</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>ter Hofstede</surname><given-names>Hadewych J.M.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Vos</surname><given-names>Fidel J.</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Vogelaar</surname><given-names>Michiel L.</given-names></name><degrees>MSc</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>van Middendorp</surname><given-names>Henri&#235;t</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Evers</surname><given-names>Andrea W.M.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>Member Scientific Advisory Boards (NWO and ZonMW). SEP Education Committee Research Master Groningen</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>National and internatinoal lectures, e.g. VGCT keynote lecture, Pruritus Meeting Muenster</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>Member of Editorial (Advisorty) Board Pain, Itch, European Journal of Pain, International Journal of Psychology, Clinical eHealth</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>MOOC interview for Celgene</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>As listed above</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NWO Vici Grant, 2017-2022. Hartstichting-ZonMW Benefit Grant, 2017-2022. ERC Consolidator Grant, 2014-2019. Dutch Arthritis Association, 2017-2020. Dutch Kidney Association, 2016-2020</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Kessels</surname><given-names>Roy P.C.</given-names></name><degrees>PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>(1) Non-profit entity: member of the scientific advisory board of the European Federation of Neuropsychological Societies</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for travel or speaker honoraria:</title><list-item><p>(1) Non-profit entity: Norwegian Neuroposychological Society, speaker honorarium ($1000) (2) Non-profit entity: International Neuropsychological Society, travel reimbursement (awards committee chair)</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>(1) Journal of the International Neuropsychological Society, Consulting editor, 2013- (2) Cognitive Processing, Advisory editor, 2006- (3) ISRN, Editorial board, 2012- (4) Journal of Neurology Research, Editorial team, 2012- (5) Tijdschrift voor Neuropsychologie, Editorial Advisory Board Member, 2010-</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>(1) (Op)nieuw geleerd, oud gedaan: Over het lerend vermogen van mensen met dementie, Utrecht, the Netherlands: Kosmos, 2011. (2) Location Learning Test - Revised, Amsterdam: Hogrefe, 2012. (3) Errorless learning in neuropsychological rehabilitation: Mechanisms, efficacy and application. London, UK: Routledge. 2018</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>(1) Netherlands Organisation for Scientific Research (NWO), Gravitation Grant 024.001.006 of the Language in Interaction Consortium (PhD grant)</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><contrib contrib-type="author"><name><surname>Kullberg</surname><given-names>Bart Jan</given-names></name><degrees>MD, PhD</degrees><author-comment content-type="disclosure"><p><list list-type="order"><title>Scientific Advisory Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Gifts:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Funding for Travel or Speaker Honoraria:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Editorial Boards:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Patents:</title><list-item><p>Inventor, patent #WO2012039614, owned by Radboud University. Cellular diagnostic test method for Lyme disease; no commercial product.</p></list-item></list></p><p><list list-type="order"><title>Publishing Royalties:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Employment, Commercial Entity:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Consultancies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Speakers' Bureaus:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Other Activities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Clinical Procedures or Imaging Studies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Commercial Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Government Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Academic Entities:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Research Support, Foundations and Societies:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options/Board of Directors Compensation:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>License Fee Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Royalty Payments, Technology or Inventions:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Research Sponsor:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Stock/Stock Options, Medical Equipment &amp; Materials:</title><list-item><p>NONE</p></list-item></list></p><p><list list-type="order"><title>Legal Proceedings:</title><list-item><p>NONE</p></list-item></list></p></author-comment></contrib><aff>From the Department of Medicine (A.B., H.J.M.t.H., F.J.V., B.J.K.), Radboud Center for Infectious Diseases (A.B., H.J.M.t.H., F.J.V., B.J.K.), and Department of Medical Psychology (M.L.V., H.v.M., A.W.M.E., R.P.C.K.), Radboud University Medical Center; Department of Medicine (F.J.V.), Sint Maartenskliniek, Nijmegen; Institute of Psychology (H.v.M., A.W.M.E.), Health, Medical, and Neuropsychology Unit, Leiden University; and Donders Institute for Brain, Cognition and Behaviour (R.P.C.K.), Radboud University, Nijmegen, <country>the Netherlands.</country></aff></contrib-group><author-notes><corresp><bold>Correspondence</bold> Dr. Berende <email>Anneleen.Berende@radboudumc.nl</email></corresp><fn fn-type="financial-disclosure"><p>Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000007186">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p></fn><fn fn-type="other"><p>The Article Processing Charge was funded by the authors.</p></fn></author-notes><pub-date pub-type="ppub"><day>26</day><month>3</month><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>3</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>92</volume><issue>13</issue><fpage>e1447</fpage><lpage>e1455</lpage><history><date date-type="received"><day>24</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>21</day><month>11</month><year>2018</year></date></history><permissions><copyright-statement>Copyright &#169; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder>American Academy of Neurology</copyright-holder><license license-type="open-access"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="NEUROLOGY2018928317.pdf"/><abstract><sec><title>Objective</title><p>To investigate whether longer-term antibiotic treatment improves cognitive performance in patients with persistent symptoms attributed to Lyme borreliosis.</p></sec><sec><title>Methods</title><p>Data were collected during the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE) trial, a randomized, placebo-controlled study. Study participants passed performance-validity testing (measure for detecting suboptimal effort) and had persistent symptoms attributed to Lyme borreliosis. All patients received a 2-week open-label regimen of intravenous ceftriaxone before the 12-week blinded oral regimen (doxycycline, clarithromycin/hydroxychloroquine, or placebo). Cognitive performance was assessed at baseline and after 14, 26, and 40 weeks with neuropsychological tests covering the cognitive domains of episodic memory, attention/working memory, verbal fluency, speed of information processing, and executive function.</p></sec><sec><title>Results</title><p>Baseline characteristics of patients enrolled (n = 239) were comparable in all treatment groups. After 14 weeks, performance on none of the cognitive domains differed significantly between the treatment arms (<italic>p</italic> = 0.49&#8211;0.82). At follow-up, no additional treatment effect (<italic>p</italic> = 0.35&#8211;0.98) or difference between groups (<italic>p</italic> = 0.37&#8211;0.93) was found at any time point. Patients performed significantly better in several cognitive domains at weeks 14, 26, and 40 compared to baseline, but this was not specific to a treatment group.</p></sec><sec><title>Conclusions</title><p>A 2-week treatment with ceftriaxone followed by a 12-week regimen of doxycycline or clarithromycin/hydroxychloroquine did not lead to better cognitive performance compared to a 2-week regimen of ceftriaxone in patients with Lyme disease&#8211;attributed persistent symptoms.</p></sec><sec><title>ClinicalTrials.gov identifier</title><p>NCT01207739.</p></sec><sec><title>Classification of evidence</title><p>This study provides Class II evidence that longer-term antibiotics in patients with borreliosis-attributed persistent symptoms does not increase cognitive performance compared to shorter-term antibiotics.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta><custom-meta><meta-name>STATUS</meta-name><meta-value>ONLINE-ONLY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>Many patients who experience persistent symptoms that are attributed to Lyme borreliosis complain of cognitive problems such as memory loss, word-finding difficulties, and concentration problems.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> However, previous studies have failed to show significant correlations between subjective memory complaints and objective test performances in patients with Lyme borreliosis and other patients.<sup><xref rid="R3" ref-type="bibr">3</xref><xref ref-type="bibr" rid="R4">&#8211;</xref><xref rid="R6" ref-type="bibr">6</xref></sup> This makes assessing neurocognitive function with objective neuropsychological tests important.</p><p>Several small studies have investigated the neurocognitive performance of patients with Lyme disease compared to healthy participants. Most found a worse performance in the patient group.<sup><xref rid="R6" ref-type="bibr">6</xref><xref ref-type="bibr" rid="R7">&#8211;</xref><xref rid="R13" ref-type="bibr">13</xref></sup> Deficits observed in patients with persistent symptoms attributed to Lyme disease are best typified as a combination of reduced processing speed and memory problems.<sup><xref rid="R9" ref-type="bibr">9</xref></sup></p><p>To date, it is unknown whether the cognitive problems reported by patients with persistent Lyme disease&#8211;attributed symptoms are due to an insufficiently treated low-grade <italic>Borrelia burgdorferi</italic> infection, remnants of past infection, or incorrect attribution to Lyme borreliosis. Although most guidelines recommend antimicrobial therapy for a maximum of 2 to 4 weeks,<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R15" ref-type="bibr">15</xref></sup> others recommend longer-term antibiotic treatment.<sup><xref rid="R16" ref-type="bibr">16</xref></sup></p><p>Previous studies have not been conclusive in proving the effects of longer-term antibiotic therapy on cognition.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R17" ref-type="bibr">17</xref><xref ref-type="bibr" rid="R18">&#8211;</xref><xref rid="R20" ref-type="bibr">20</xref></sup> Furthermore, the trials performed were small (n = 129 and n = 37).<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> The present study, the largest to date, was performed to evaluate the effect of prolonged antimicrobial treatment compared to shorter-term treatment on neurocognitive function in patients with symptoms attributed to Lyme borreliosis.</p><sec sec-type="methods" id="s1"><title>Methods</title><sec id="s1-1"><title>Study design and participants</title><p>The data for this neurocognitive study were collected as secondary outcomes of the Persistent Lyme Empiric Antibiotic Study Europe (PLEASE), a multicenter, placebo-controlled, double-blind randomized clinical trial that was performed in the Netherlands at 2 locations (Sint Maartenskliniek and Radboud University Medical Center). From October 2010 through June 2013, patients were enrolled in this trial. The study design and protocol, inclusion and exclusion criteria,<sup><xref rid="R21" ref-type="bibr">21</xref></sup> and main outcomes were previously published.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> Patients with ongoing symptoms such as musculoskeletal pain, neuralgia, sensory disturbances, or cognitive complaints were included if they also had <italic>B burgdorferi</italic> immunoglobulin (Ig) G or IgM antibodies or if the complaints were temporally linked to an erythema migrans or otherwise proven symptomatic Lyme borreliosis.</p></sec><sec id="s1-2"><title>Standard protocol approvals, registrations, and patient consents</title><p>The local ethics committee has approved the PLEASE protocol (CMO region Arnhem-Nijmegen, 2009/187, NL27344.091.09). All participants provided written informed consent. The trial was registered with <ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> (NCT01207739).</p></sec><sec id="s1-3"><title>Randomization and masking</title><p>Computerized randomization distributed patients into 3 groups in a 1:1:1 ratio. The randomization was balanced by minimization for duration of symptoms (&lt;1 or &#8805;1 year), age (&lt;40 or &#8805;40 years), sex, and baseline RAND-36 Health Status Inventory Global Health Composite score.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> An independent web manager entered the randomization list, consisting of consecutive medication numbers, into a secured web-based database. None of the participants or personnel involved in the trial (apart from the web manager and study pharmacist) were aware of the assignments to study groups.</p></sec><sec id="s1-4"><title>Classification of evidence</title><p>The primary research question is whether longer-term antibiotic treatment with 2 weeks of ceftriaxone followed by 12 weeks of doxycycline or clarithromycin/hydroxychloroquine improves cognitive performance in patients with persistent symptoms attributed to Lyme borreliosis compared to shorter-term antibiotic treatment with 2 weeks of ceftriaxone. This trial provides Class II evidence that longer-term treatment does not lead to additional improvement.</p></sec><sec id="s1-5"><title>Intervention</title><p>All patients were treated with open-label intravenous ceftriaxone daily for 2 weeks. After completion, patients started on a blinded and randomized 12-week oral regimen of doxycycline, clarithromycin-hydroxychloroquine, or placebo. The study drugs and placebo had an identical appearance. More details on the intervention have been provided in the study protocol of the PLEASE trial.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p></sec><sec id="s1-6"><title>Procedures</title><p>Cognitive performance was assessed at baseline, after end of treatment (EOT) at 14 weeks, at 26 weeks, and at 40 weeks with an extensive neuropsychological test battery covering the 5 major cognitive domains: episodic memory, attention/working memory, fluency, speed of information processing, and executive function. We measured episodic memory with the Rey Auditory Verbal Learning Test, attention/working memory with the Digit Span Test, language with the Category Fluency Test, and speed of information processing with the Trail Making Test Part A, the average speed of cards I and II from the Stroop Color-Word Test, and the Symbol-Digit Substitution Test. We assessed executive function with the Trail Making Test Interference Score (Part B/Part A) and the Stroop Interference Score (card III/average of cards I and II). The raw test scores were standardized into <italic>z</italic> scores by use of the pooled mean of baseline scores of the entire study sample. The compound score for each cognitive domain was obtained by calculating the mean of the <italic>z</italic> scores for tests making up that domain. Higher scores represent better performance. Further details on the neuropsychological assessment have been published previously in a report on our protocol.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> Furthermore, we administered the Amsterdam Short Term Memory Test at baseline to identify participants who displayed suboptimal effort affecting performance validity. This test only appears to be a difficult task; even patients with brain damage can perform well.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> Poor performance on this task indicates suboptimal mental effort. The cutoff score for this performance validity test is 85 points (maximum score 90), with a sensitivity of 86% and a specificity of 87%. Because we aimed to obtain an optimal specificity (i.e., &gt;90%), we included only patients scoring &#8805;83 points (with a specificity of 93%) in the analyses to exclude participants who displayed suboptimal effort.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup></p></sec><sec id="s1-7"><title>Statistical analysis</title><p>In this study, we report secondary outcomes of the main trial, the PLEASE study. The analyses include only patients who were randomly assigned to a study group, received at least 1 dose of ceftriaxone (modified intention-to-treat population), and displayed sufficient performance validity at baseline (Amsterdam Short Term Memory Test score &#8805;83). For descriptive purposes, we also classified individuals at baseline as having a clinically impaired cognitive performance using Multivariate Normative Comparisons<sup><xref rid="R26" ref-type="bibr">26</xref></sup> based on a large Dutch normative data set from the Advanced Neuropsychological Diagnostic Infrastructure.<sup><xref rid="R27" ref-type="bibr">27</xref></sup></p><p>We compared the 3 study groups at week 14 (EOT) with analysis of covariance, including baseline domain score as a covariate. Missing data at week 14 were imputed if they occurred in &lt;5% of the cases<sup><xref rid="R28" ref-type="bibr">28</xref></sup> with the mean of the treatment group at that assessment moment. We performed linear mixed models to estimate the duration of the potential intervention effect, including all 3 posttreatment assessments (14, 26, and 40 weeks). All models contained the baseline value of the dependent variable, time, study group treatment, and time-by-treatment interaction.</p><p>The &#945; level was set at 0.05 (2 tailed), and 95% confidence intervals are reported when appropriate. For pairwise comparisons of the 5 domains among the 3 study groups at different endpoints, Bonferroni correction was used (by adjusting &#945; to 0.01) to reduce the probability of family-wise (type I) error. Sensitivity analyses included all analyses without imputation. SPSS software version 22 was used to perform the statistical analyses.</p></sec><sec sec-type="data-availability" id="s1-8"><title>Data availability</title><p>Anonymized data, related documents such as study protocol, and statistical analysis will be shared by request from any qualified investigator for 5 years after the date of publication.</p></sec></sec><sec sec-type="results" id="s2"><title>Results</title><p>Of the 281 patients randomized, 85% (n = 239) displayed sufficient performance validity on the cognitive tests at baseline (<xref ref-type="fig" rid="F1">figure 1</xref>). No baseline differences were found between the 3 treatment groups, including baseline neuropsychological performance (<xref rid="T1" ref-type="table">table 1</xref>), apart from the percentage of patients with a job, which significantly differed between groups. At baseline, 7 of 239 patients were classified as having a clinically impaired cognitive performance compared to Dutch normative data.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Flowchart</title><p>.</p></caption><graphic xlink:href="NEUROLOGY2018928317FF1"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Baseline characteristics<sup>a</sup></p></caption><graphic xlink:href="NEUROLOGY2018928317TT1"/></table-wrap><p>The neuropsychological performance (i.e., the mean <italic>z</italic> score per domain) at EOT (14 weeks), corrected for baseline performance and sex, did not significantly differ between treatment groups for any of the domains, with <italic>p</italic> values ranging from 0.49 to 0.82 (<xref rid="T2" ref-type="table">table 2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Neuropsychological performance at EOT (14 weeks)<sup>a</sup></p></caption><graphic xlink:href="NEUROLOGY2018928317TT2"/></table-wrap><p><xref ref-type="fig" rid="F2">Figure 2</xref> shows the mean performance per group for each neuropsychological domain over time. The differences between the various time points compared to baseline are depicted in <xref rid="T3" ref-type="table">table 3</xref>. The performance on 2 domains, episodic memory and speed of information, significantly improved between baseline and EOT in all randomization groups. Similarly, at 26 and 40 weeks, several domains showed higher scores compared to baseline.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Mean <italic>z</italic> score (95% confidence interval) per treatment group per neuropsychological domain at all study visits</title><p>(A) Episodic memory, (B) working memory, (C) fluency, (D) speed of information processing, and (E) executive function.</p></caption><graphic xlink:href="NEUROLOGY2018928317FF2"/></fig><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Treatment effect at different endpoints (14, 26, and 40 weeks compared to baseline)</p></caption><graphic xlink:href="NEUROLOGY2018928317TT3"/></table-wrap><p>However, no additional long-term treatment effects were seen in mixed-model analyses (the difference between the treatment arms did not change over time) for any of the domains; <italic>p</italic> values ranged from 0.35 to 0.98 for the time-by-treatment interaction. No significant difference was found between the 3 treatment groups at any time point during follow-up in neuropsychological performance either (<italic>p</italic> values ranging from 0.37 to 0.93). All sensitivity analyses yielded results similar to those of the main analyses. Several post hoc analyses were also done. Subset analyses with patients who had symptoms for &lt;1 year (n = 46) did not show a significant difference between treatment groups. Excluding patients who did not report subjective cognitive complaints at baseline (n = 32) did not yield different results, nor did post hoc analyses on the subgroup of patients with severe subjective symptoms as measured by the Cognitive Failures Questionnaire.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> With a cutoff value for the Cognitive Failures Questionnaire set at 44, 111 patients were considered to have severe neurocognitive symptoms. Finally, subgroup analyses including only patients who had a high burden of symptoms (i.e., those who were on sick leave or disability support, n = 81) also did not show a significant difference between placebo and antimicrobial treatment groups. Using analysis of covariance, with sick leave/disability and baseline cognitive function as covariates, we found no significant difference between treatment groups.</p></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>This study showed that prolonged antibiotic treatment for 3 months in patients with persistent Lyme borreliosis&#8211;attributed symptoms does not have an additional beneficial effect on cognitive performance compared to short-term treatment.</p><p>Previous case series have suggested a significant cognitive improvement on most domains after antibiotic treatment.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> Two randomized controlled treatment trials have also demonstrated significant improvement of objective test scores after treatment compared to baseline performance.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> However, no significant differences were found between those receiving antibiotics and those receiving placebo in 1 trial,<sup><xref rid="R5" ref-type="bibr">5</xref></sup> and the other trial did not show sustainable effects of antibiotic treatment on cognition.<sup><xref rid="R17" ref-type="bibr">17</xref></sup> In our trial, mixed-model analyses showed no difference over time. Cognitive improvements were found at weeks 14, 26, and 40 only when the separate domains were directly compared with baseline, and changes over time were at most in the small to moderate range. Because an improvement was seen in all treatment groups, including the placebo control group, the observed changes appear to be neither clinically relevant nor treatment specific. The global difference found over time may be the result of a placebo effect, nonspecific practice effects, spontaneous improvement over time, or a combination of these.</p><p>The present study is the largest trial performed to date. It was specifically designed prospectively to study treatment outcomes, including cognitive performance, using a strictly controlled design.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup> In addition, our study is the first to take suboptimal cognitive effort into account in the neuropsychological assessment by selecting only patients who displayed sufficient performance validity. Kaplan et al.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> have investigated the personality traits of participants and investigated symptom validity to some extent by examining the patients' ability to present a false impression using the Minnesota Multiphasic Personality Inventory-2. However, that does not compare to our way of taking suboptimal cognitive effort explicitly into account through performance validity testing.</p><p>A limitation of our study may relate to missing values. To reduce the influence of missing values, mixed-model analyses were performed. In these analyses, no significant differences between groups on any of the domains were observed.</p><p>While a ceiling effect may be considered, because only a few patients were overall cognitively impaired at baseline, none of the raw scores were at or near ceiling for any of the tests at various endpoints. The mean performances per test were typically in the midrange between the minimally and maximally possible scores, leaving sufficient room for improvement.</p><p>The fact that we did not include only patients with subjective cognitive complaints could be seen as another limitation. However, our patient population is representative of the real-life population of patients with Lyme borreliosis, improving the external validity. Moreover, only 32 of 280 patients did not report subjective cognitive complaints at baseline. Post hoc analyses excluding those 32 patients did not yield different results; i.e., there was no significant difference between groups at EOT.</p><p>Finally, because the study was not specifically powered for detecting neuropsychological test outcomes, the results must be seen as preliminary.</p><p>Future studies on treatment of cognitive function in individuals with Lyme borreliosis may specifically focus on the small group of patients with objectively impaired cognitive performance.</p><p>Our study suggests that cognitive performance as assessed by validated tests does not improve with longer antibiotic treatment compared to shorter-term treatment in patients with persistent symptoms attributed to Lyme borreliosis.</p></sec></body><back><fn-group><fn fn-type="supplementary-material"><p>Class of Evidence: <ext-link ext-link-type="uri" xlink:href="http://NPub.org/coe">NPub.org/coe</ext-link></p></fn><fn fn-type="supplementary-material"><p>Podcast: <ext-link ext-link-type="uri" xlink:href="http://NPub.org/s40f5s">NPub.org/s40f5s</ext-link></p></fn><fn fn-type="supplementary-material"><p>CME Course: <ext-link ext-link-type="uri" xlink:href="http://NPub.org/cmelist">NPub.org/cmelist</ext-link></p></fn></fn-group><ack><title>Acknowledgment</title><p>The authors thank Dr. Joost A. Agelink van Rentergem, University of Amsterdam, for his assistance with the Advanced Neuropsychological Diagnostics Infrastructure analyses.</p></ack><app-group><app id="A1"><label>Appendix</label><title>Authors</title><p><table-wrap id="TU1" orientation="portrait" position="anchor"><graphic xlink:href="NEUROLOGY2018928317TTU1"/></table-wrap></p></app></app-group><sec sec-type="funding"><title>Study funding</title><p content-type="funding">Funded by the Netherlands National Organization for Scientific Research (ID ZonMw 171002304).</p></sec><sec sec-type="disclosure"><title>Disclosure</title><p content-type="disclosure">The authors report no disclosures relevant to the manuscript. Go to <ext-link ext-link-type="uri" xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000007186">Neurology.org/N</ext-link> for full disclosures.</p></sec><glossary><title>Glossary</title><def-list><def-item><term id="G1">EOT</term><def><p>end of treatment</p></def></def-item><def-item><term id="G2">Ig</term><def><p>immunoglobulin</p></def></def-item><def-item><term id="G3">PLEASE</term><def><p>Persistent Lyme Empiric Antibiotic Study Europe</p></def></def-item></def-list></glossary><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aucott</surname><given-names>JN</given-names></name>, <name name-style="western"><surname>Rebman</surname><given-names>AW</given-names></name>, <name name-style="western"><surname>Crowder</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Kortte</surname><given-names>KB</given-names></name></person-group>
<article-title>Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?</article-title>
<source>Qual Life Res</source>
<year>2013</year>;<volume>22</volume>:<fpage>75</fpage>&#8211;<lpage>84</lpage>.<pub-id pub-id-type="pmid">22294245</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logigian</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Steere</surname><given-names>AC</given-names></name></person-group>
<article-title>Chronic neurologic manifestations of Lyme disease</article-title>. <source>N Engl J Med</source>
<year>1990</year>;<volume>323</volume>:<fpage>1438</fpage>&#8211;<lpage>1444</lpage>.<pub-id pub-id-type="pmid">2172819</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bermeo-Ovalle</surname><given-names>A</given-names></name></person-group>
<article-title>Do we know what we think we know? Reconciling subjective complaints and objective cognitive testing in older adults with epilepsy</article-title>. <source>Epilepsy Curr</source>
<year>2016</year>;<volume>16</volume>:<fpage>230</fpage>&#8211;<lpage>231</lpage>.<pub-id pub-id-type="pmid">27582656</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galioto</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Blum</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Tremont</surname><given-names>G</given-names></name></person-group>
<article-title>Subjective cognitive complaints versus objective neuropsychological performance in older adults with epilepsy</article-title>. <source>Epilepsy Behav</source>
<year>2015</year>;<volume>51</volume>:<fpage>48</fpage>&#8211;<lpage>52</lpage>.<pub-id pub-id-type="pmid">26255885</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaplan</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Trevino</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>GM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cognitive function in post-treatment Lyme disease: do additional antibiotics help?</article-title>
<source>Neurology</source>
<year>2003</year>;<volume>60</volume>:<fpage>1916</fpage>&#8211;<lpage>1922</lpage>.<pub-id pub-id-type="pmid">12821733</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ravdin</surname><given-names>LD</given-names></name>, <name name-style="western"><surname>Hilton</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Primeau</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Clements</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Barr</surname><given-names>WB</given-names></name></person-group>
<article-title>Memory functioning in Lyme borreliosis</article-title>. <source>J Clin Psychiatry</source>
<year>1996</year>;<volume>57</volume>:<fpage>282</fpage>&#8211;<lpage>286</lpage>.<pub-id pub-id-type="pmid">8666568</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eikeland</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ljostad</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Mygland</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Herlofson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Lohaugen</surname><given-names>GC</given-names></name></person-group>
<article-title>European neuroborreliosis: neuropsychological findings 30 months post-treatment</article-title>. <source>Eur J Neurol</source>
<year>2012</year>;<volume>19</volume>:<fpage>480</fpage>&#8211;<lpage>487</lpage>.<pub-id pub-id-type="pmid">21999112</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaudino</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Coyle</surname><given-names>PK</given-names></name>, <name name-style="western"><surname>Krupp</surname><given-names>LB</given-names></name></person-group>
<article-title>Post-Lyme syndrome and chronic fatigue syndrome: neuropsychiatric similarities and differences</article-title>. <source>Arch Neurol</source>
<year>1997</year>;<volume>54</volume>:<fpage>1372</fpage>&#8211;<lpage>1376</lpage>.<pub-id pub-id-type="pmid">9362985</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keilp</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Corbera</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Slavov</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Taylor</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Sackeim</surname><given-names>HA</given-names></name>, <name name-style="western"><surname>Fallon</surname><given-names>BA</given-names></name></person-group>
<article-title>WAIS-III and WMS-III performance in chronic Lyme disease</article-title>. <source>J Int Neuropsychol Soc</source>
<year>2006</year>;<volume>12</volume>:<fpage>119</fpage>&#8211;<lpage>129</lpage>.<pub-id pub-id-type="pmid">16433951</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Krupp</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Masur</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Schwartz</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Cognitive functioning in late Lyme borreliosis</article-title>. <source>Arch Neurol</source>
<year>1991</year>;<volume>48</volume>:<fpage>1125</fpage>&#8211;<lpage>1129</lpage>.<pub-id pub-id-type="pmid">1953395</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollina</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Sliwinski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Squires</surname><given-names>NK</given-names></name>, <name name-style="western"><surname>Krupp</surname><given-names>LB</given-names></name></person-group>
<article-title>Cognitive processing speed in Lyme disease</article-title>. <source>Neuropsychiatry Neuropsychol Behav Neurol</source>
<year>1999</year>;<volume>12</volume>:<fpage>72</fpage>&#8211;<lpage>78</lpage>.<pub-id pub-id-type="pmid">10082336</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shadick</surname><given-names>NA</given-names></name>, <name name-style="western"><surname>Phillips</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Logigian</surname><given-names>EL</given-names></name>, <etal>et al</etal></person-group>
<article-title>The long-term clinical outcomes of Lyme disease: a population-based retrospective cohort study</article-title>. <source>Ann Intern Med</source>
<year>1994</year>;<volume>121</volume>:<fpage>560</fpage>&#8211;<lpage>567</lpage>.<pub-id pub-id-type="pmid">8085687</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Westervelt</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>McCaffrey</surname><given-names>RJ</given-names></name></person-group>
<article-title>Neuropsychological functioning in chronic Lyme disease</article-title>. <source>Neuropsychol Rev</source>
<year>2002</year>;<volume>12</volume>:<fpage>153</fpage>&#8211;<lpage>177</lpage>.<pub-id pub-id-type="pmid">12428915</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mygland</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lj&#248;stad</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Fingerle</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Rupprecht</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Schmutzhard</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Steiner</surname><given-names>I</given-names></name></person-group>
<article-title>EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis</article-title>. <source>Eur J Neurol</source>
<year>2010</year>;<volume>17</volume>, <fpage>8</fpage>&#8211;<lpage>4</lpage>.<pub-id pub-id-type="pmid">19930447</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wormser</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Dattwyler</surname><given-names>RJ</given-names></name>, <name name-style="western"><surname>Shapiro</surname><given-names>ED</given-names></name>, <etal>et al</etal></person-group>
<article-title>The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America</article-title>. <source>Clin Infect Dis</source>
<year>2006</year>;<volume>43</volume>:<fpage>1089</fpage>&#8211;<lpage>1134</lpage>.<pub-id pub-id-type="pmid">17029130</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Johnson</surname><given-names>LB</given-names></name>, <name name-style="western"><surname>Maloney</surname><given-names>EL</given-names></name></person-group>
<article-title>Evidence assessments and guideline recommendations in Lyme disease: the clinical management of known tick bites, erythema migrans rashes and persistent disease</article-title>. <source>Expert Rev Anti Infect Ther</source>
<year>2014</year>;<volume>12</volume>:<fpage>1103</fpage>&#8211;<lpage>1135</lpage>.<pub-id pub-id-type="pmid">25077519</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fallon</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Keilp</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Corbera</surname><given-names>KM</given-names></name>, <etal>et al</etal></person-group>
<article-title>A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy</article-title>. <source>Neurology</source>
<year>2008</year>;<volume>70</volume>:<fpage>992</fpage>&#8211;<lpage>1003</lpage>.<pub-id pub-id-type="pmid">17928580</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halperin</surname><given-names>JJ</given-names></name>, <name name-style="western"><surname>Pass</surname><given-names>HL</given-names></name>, <name name-style="western"><surname>Anand</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Luft</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Volkman</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Dattwyler</surname><given-names>RJ</given-names></name></person-group>
<article-title>Nervous system abnormalities in Lyme disease</article-title>. <source>Ann NY Acad Sci</source>
<year>1988</year>;<volume>539</volume>:<fpage>24</fpage>&#8211;<lpage>34</lpage>.<pub-id pub-id-type="pmid">3190096</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logigian</surname><given-names>EL</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Steere</surname><given-names>AC</given-names></name></person-group>
<article-title>Successful treatment of Lyme encephalopathy with intravenous ceftriaxone</article-title>. <source>J Infect Dis</source>
<year>1999</year>;<volume>180</volume>:<fpage>377</fpage>&#8211;<lpage>383</lpage>.<pub-id pub-id-type="pmid">10395852</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klempner</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>LT</given-names></name>, <name name-style="western"><surname>Evans</surname><given-names>J</given-names></name>, <etal>et al</etal></person-group>
<article-title>Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease</article-title>. <source>N Engl J Med</source>
<year>2001</year>;<volume>345</volume>:<fpage>85</fpage>&#8211;<lpage>92</lpage>.<pub-id pub-id-type="pmid">11450676</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berende</surname><given-names>A</given-names></name>, <name name-style="western"><surname>ter Hofstede</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Donders</surname><given-names>AR</given-names></name>, <etal>et al</etal></person-group>
<article-title>Persistent Lyme Empiric Antibiotic Study Europe (PLEASE): design of a randomized controlled trial of prolonged antibiotic treatment in patients with persistent symptoms attributed to Lyme borreliosis</article-title>. <source>BMC Infect Dis</source>
<year>2014</year>;<volume>14</volume>:<fpage>543</fpage>.<pub-id pub-id-type="pmid">25318999</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Berende</surname><given-names>A</given-names></name>, <name name-style="western"><surname>ter Hofstede</surname><given-names>HJ</given-names></name>, <name name-style="western"><surname>Vos</surname><given-names>FJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Randomized trial of longer-term therapy for symptoms attributed to Lyme disease</article-title>. <source>N Engl J Med</source>
<year>2016</year>;<volume>374</volume>:<fpage>1209</fpage>&#8211;<lpage>1220</lpage>.<pub-id pub-id-type="pmid">27028911</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Hays</surname><given-names>RD</given-names></name></person-group>
<source>RAND-36 Health Status Inventory</source>. <publisher-loc>San Antonio</publisher-loc>: <publisher-name>Psychological Corp</publisher-name>; <year>1998</year>.</mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schagen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schmand</surname><given-names>B</given-names></name>, <name name-style="western"><surname>de Sterke</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Lindeboom</surname><given-names>J</given-names></name></person-group>
<article-title>Amsterdam Short-Term Memory Test: a new procedure for the detection of feigned memory deficits</article-title>. <source>J Clin Exp Neuropsychol</source>
<year>1997</year>;<volume>19</volume>:<fpage>43</fpage>&#8211;<lpage>51</lpage>.<pub-id pub-id-type="pmid">9071640</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Schmand</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lindeboom</surname><given-names>J</given-names></name></person-group>
<source>Amsterdam Short Term Memory Test: Manual</source>. <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Hogrefe</publisher-name>; <year>2005</year>.</mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agelink van Rentergem</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Murre</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Huizenga</surname><given-names>HM</given-names></name></person-group>
<article-title>Multivariate normative comparisons using an aggregated database</article-title>. <source>PLoS One</source>
<year>2017</year>;<volume>12</volume>:<fpage>e0173218</fpage>.<pub-id pub-id-type="pmid">28267796</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Vent</surname><given-names>NR</given-names></name>, <name name-style="western"><surname>Agelink van Rentergem</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Schmand</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Murre</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Consortium</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Huizenga</surname><given-names>HM</given-names></name></person-group>
<article-title>Advanced Neuropsychological Diagnostics Infrastructure (ANDI): a normative database created from control datasets</article-title>. <source>Front Psychol</source>
<year>2016</year>;<volume>7</volume>:<fpage>1601</fpage>.<pub-id pub-id-type="pmid">27812340</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Graham</surname><given-names>JW</given-names></name></person-group>
<article-title>Missing data analysis: making it work in the real world</article-title>. <source>Annu Rev Psychol</source>
<year>2009</year>;<volume>60</volume>:<fpage>549</fpage>&#8211;<lpage>576</lpage>.<pub-id pub-id-type="pmid">18652544</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broadbent</surname><given-names>DE</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>PF</given-names></name>, <name name-style="western"><surname>FitzGerald</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Parkes</surname><given-names>KR</given-names></name></person-group>
<article-title>The Cognitive Failures Questionnaire (CFQ) and its correlates</article-title>. <source>Br J Clin Psychol</source>
<year>1982</year>;<volume>21</volume>(<issue>pt 1</issue>):<fpage>1</fpage>&#8211;<lpage>16</lpage>.<pub-id pub-id-type="pmid">7126941</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hochstenbach</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Mulder</surname><given-names>T</given-names></name>, <name name-style="western"><surname>van Limbeek</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Donders</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Schoonderwaldt</surname><given-names>H</given-names></name></person-group>
<article-title>Cognitive decline following stroke: a comprehensive study of cognitive decline following stroke</article-title>. <source>J Clin Exp Neuropsychol</source>
<year>1998</year>;<volume>20</volume>:<fpage>503</fpage>&#8211;<lpage>517</lpage>.<pub-id pub-id-type="pmid">9892054</pub-id></mixed-citation></ref></ref-list></back></article>